Cargando…
A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
BACKGROUND: The COVID-19 pandemic reached Europe in early 2020. Convalescent plasma is used without a consistent evidence of efficacy. Our hypothesis is that passive immunization with plasma collected from patients having contracted COVID-19 and developed specific neutralizing antibodies may allevia...
Autores principales: | Misset, Benoît, Hoste, Eric, Donneau, Anne-Françoise, Grimaldi, David, Meyfroidt, Geert, Moutschen, Michel, Compernolle, Veerle, Gothot, André, Desmecht, Daniel, Garigliany, Mutien, Najdovski, Tome, Laterre, Pierre-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719725/ https://www.ncbi.nlm.nih.gov/pubmed/33287790 http://dx.doi.org/10.1186/s12890-020-01361-x |
Ejemplares similares
-
Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
por: Misset, Benoît, et al.
Publicado: (2021) -
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
por: Devos, Timothy, et al.
Publicado: (2022) -
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
por: Devos, Timothy, et al.
Publicado: (2020) -
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
por: Devos, Timothy, et al.
Publicado: (2020) -
N-acetylcysteine lacks universal inhibitory activity against influenza A viruses
por: Garigliany, Mutien-Marie O, et al.
Publicado: (2011)